pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BRISTOL MYERS SQUIBB · news · pharmadog
← back to BRISTOL MYERS SQUIBB
News mentioning BRISTOL MYERS SQUIBB
305
stories
Aug 21, 26
Shareholder pressures Capricor; Lilly dives deeper into vaccines
biopharma dive
Aug 20, 26
Chutes & Ladders—Neumora shuffles leadership ahead of IND
fiercebiotech
Aug 20, 26
Chai tees up Bristol Myers Squibb AI antibody discovery collab
fiercebiotech
Aug 19, 26
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
Aug 19, 26
Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China
endpoints
Aug 18, 26
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
Aug 18, 26
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
Aug 17, 26
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
Aug 17, 26
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
Aug 14, 26
Cytokinetics brings patent suit against Bristol Myers, escalating rivalry
endpoints
Aug 14, 26
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
biopharma dive
Aug 14, 26
STAT+: PBMs agree to display TrumpRx drug prices
stat
Aug 14, 26
STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
stat
Aug 14, 26
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
Aug 14, 26
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
stat
Aug 14, 26
BMS welcomes new multiple myeloma drug as generics batter current portfolio
biospace
Aug 14, 26
MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
fiercebiotech
Aug 13, 26
FDA approves Bristol Myers' multiple myeloma successor
endpoints
Aug 12, 26
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
Aug 11, 26
AbbVie, Novartis and Bristol Myers file 340B lawsuits in Illinois
endpoints
Aug 10, 26
Bristol Myers details new $2.3B manufacturing campus in Houston
endpoints
Aug 10, 26
BMS picks Texas for new $2.3B manufacturing campus
biospace
Aug 10, 26
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
Aug 10, 26
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
biospace
Aug 10, 26
Recon: BMS plans $2.3B Houston manufacturing site; MHRA approves Lilly weight-loss drug for weight loss, type 2 diabetes
raps
Aug 7, 26
Why Big Pharma is chasing the industry’s most-powerful supercomputer
biopharma dive
Aug 6, 26
Replimune rebounds to win FDA approval of melanoma drug
biopharma dive
Aug 6, 26
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
Aug 6, 26
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
Aug 6, 26
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
← prev
page 6 of 11
next →
